Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:49:33.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the safety and efficacy evaluation of Grapiprant in combination with Pembrolizumab for patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:20:33.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to provide a detailed description of eligibility criteria for clinical research, including examples such as general health condition or prior treatments. The new text also directs users to 'Learn About Studies' for more information on clinical research.
    Difference
    27%
    Check dated 2024-05-22T20:30:18.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:16:05.000Z thumbnail image

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.